Blood-brain barrier damage associates with glia-related cytokines in the cerebrospinal fluid of patients with Multiple Sclerosis

M Puthenparampil; A Marin; G Zanotelli; V A Mauceri; F De Napoli; M Gaggiola; A Miscioscia; M Ponzano; F Bovis; P Perini; F Rinaldi; B Molon; P Gallo

doi:10.1016/j.msard.2023.105403

Blood-brain barrier damage associates with glia-related cytokines in the cerebrospinal fluid of patients with Multiple Sclerosis

Mult Scler Relat Disord. 2024 Feb:82:105403. doi: 10.1016/j.msard.2023.105403. Epub 2024 Jan 3.

Authors

M Puthenparampil¹, A Marin², G Zanotelli³, V A Mauceri³, F De Napoli³, M Gaggiola³, A Miscioscia⁴, M Ponzano⁵, F Bovis⁵, P Perini³, F Rinaldi³, B Molon², P Gallo³

Affiliations

¹ Department of Neurosciences, University of Padua, Padua, Italy; Multiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy. Electronic address: marco.puthenparmapil@unipd.it.
² Department of Biomedical Sciences, University of Padua, Padua, Italy.
³ Department of Neurosciences, University of Padua, Padua, Italy; Multiple Sclerosis Centre, Azienda Ospedaliera di Padova, Padua, Italy.
⁴ Department of Neurosciences, University of Padua, Padua, Italy.
⁵ Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy.

PMID: 38184910
DOI: 10.1016/j.msard.2023.105403

Abstract

Background: The presence of Blood-Brain Barrier (BBB) dysfunction is defined by albumin quotient (Q_ALB) and characterize a group of Multiple Sclerosis (MS) patients at clinical onset. We evaluated the concentration in cerebrospinal fluid (CSF) of 87 cytokines, to better characterize the CSF inflammatory pattern in presence of BBB damage.

Materials and method: In an exploratory cohort, CSF cytokines were evaluated by means of Multiplex technology (Bio-Plex Pro-Human Cytokine, GF and Diabetes 27-Plex Panel, Bio-Plex Pro-Human Chemokines 40-Plex Panel, Bio-Plex Pro-Human Inflammation Assays 37-Plex Panel) in a cohort of Other Not Inflammatory Neurological Disorders (ONIND) and in cohort of patients with MS, stratified according to BBB damage into Q_ALB⁺ and Q_ALB^- MS patients. In the validation cohort, we evaluated the relevant molecules in a cohort of MS patients, stratified again into Q_ALB⁺ and Q_ALB^-, including also Neurofilament Light (NfL) and Chitinase 3-like 1 (CHI3L1) CSF concentration.

Results: While MIP-1α, CXCL-13, and CCL-22 CSF concentrations were higher in both MS groups compared to ONIND, in Q_ALB⁺ MS CSF concentrations of CXCL-9 (17.85 ± 4.69 pg/mL), CXCL-10 (476.5 ± 324.3 pg/mL), and IL-16 (96.08 ± 86.17 pg/mL) were higher than in Q_ALB^- MS (8.98 ± 5368 pg/mL, p < 0.005, 281.0 ± 180.9 pg/mL, p < 0.05, and 47.35 ± 36.87 pg/mL, p < 0.005, respectively) and ONIND (8.98 ± 5368 pg/mlL, p < 0.005, 281.0 ± 180.9 pg/mL, p < 0.005, and 47.35 ± 36.87 pg/mL, p < 0.001, respectively). A strong correlation was observed between CXCL-9 and CXCL-10 in all MS groups (all r>0.75, all p < 0.001). In the validation cohort again CXCL-10 CSF concentration were higher in Q_ALB⁺ MS than in Q_ALB^- MS (94.25 ± 64.75 vs 153.8 ± 99.52, p < 0.05), while no difference was observed in serum. CSF NfL (1642 ± 1963 vs 3231 ± 3492 pg/mL, p < 0.05) and CHI3L1 (183.9 ± 86.62 vs 262 ± 137.5 ng/mL, p < 0.05) were increased in Q_ALB⁺ MS.

Conclusions: BBB damage in MS is linked to a specific CSF cytokines pattern (CXCL-9, CXCL-10, IL-16), that are also involved in astrocyte-microglia interaction. To what extent their continuous production in the CNS may mark a more severe disease course merits to be investigated.

Keywords: Albumin quotient; CXCL-10; Cerebrospinal Fluid; Mutliple sclerosis; Q(ALB).

MeSH terms

Biomarkers / cerebrospinal fluid
Blood-Brain Barrier
Humans
Interleukin-16
Multiple Sclerosis*
Nervous System Diseases*
Neuroglia

Substances

Interleukin-16
Biomarkers